141 related articles for article (PubMed ID: 36468189)
1. A universal cell-free DNA approach for response prediction to preoperative chemoradiation in rectal cancer.
Grinshpun A; Kustanovich A; Neiman D; Lehmann-Werman R; Zick A; Meir K; Vainer E; Granit RZ; Arad A; Daskal N; Schwartz R; Sapir E; Maoz M; Tahover E; Moss J; Ben-Dov IZ; Peretz T; Hubert A; Shemer R; Dor Y
Int J Cancer; 2023 Apr; 152(7):1444-1451. PubMed ID: 36468189
[TBL] [Abstract][Full Text] [Related]
2. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
3. Evaluation of Changes in Circulating Cell-Free DNA as an Early Predictor of Response to Chemoradiation in Rectal Cancer-A Pilot Study.
Ong WL; Lunca S; Morarasu S; Musina AM; Puscasu A; Iacob S; Iftincai I; Marinca A; Ivanov I; Roata CE; Velenciuc N; Dimofte G
Medicina (Kaunas); 2023 Sep; 59(10):. PubMed ID: 37893461
[No Abstract] [Full Text] [Related]
4. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
6. Prediction of Poor Response to Neoadjuvant Chemoradiation in Patients With Rectal Cancer Using a DNA Repair Deregulation Score: Picking the Losers Instead of the Winners.
Jimenez L; Perez RO; São Julião GP; Vailati BB; Fernandez LM; Gama-Rodrigues J; Habr-Gama A; DeVecchio J; Kalady MF; Camargo AA
Dis Colon Rectum; 2020 Mar; 63(3):300-309. PubMed ID: 31842156
[TBL] [Abstract][Full Text] [Related]
7. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
[TBL] [Abstract][Full Text] [Related]
8. Utility of Circulating Free DNA Fragmentomics in the Prediction of Pathological Response after Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Wang Y; Fan X; Bao H; Xia F; Wan J; Shen L; Wang Y; Zhang H; Wei Y; Wu X; Shao Y; Li X; Xu Y; Cai S; Zhang Z
Clin Chem; 2023 Jan; 69(1):88-99. PubMed ID: 36308331
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
10. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer.
Serna G; Ruiz-Pace F; Hernando J; Alonso L; Fasani R; Landolfi S; Comas R; Jimenez J; Elez E; Bullman S; Tabernero J; Capdevila J; Dienstmann R; Nuciforo P
Ann Oncol; 2020 Oct; 31(10):1366-1375. PubMed ID: 32569727
[TBL] [Abstract][Full Text] [Related]
11. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
13. One-level step section histological analysis is insufficient to confirm complete pathological response after neoadjuvant chemoradiation for rectal cancer.
Pereira MA; Dias AR; Faraj SF; Nahas CSR; Imperiale AR; Marques CFS; Cotti GC; Azevedo BC; Nahas SC; de Mello ES; Ribeiro U
Tech Coloproctol; 2017 Sep; 21(9):745-754. PubMed ID: 28819868
[TBL] [Abstract][Full Text] [Related]
14. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
[No Abstract] [Full Text] [Related]
15. MRI features and texture analysis for the early prediction of therapeutic response to neoadjuvant chemoradiotherapy and tumor recurrence of locally advanced rectal cancer.
Park H; Kim KA; Jung JH; Rhie J; Choi SY
Eur Radiol; 2020 Aug; 30(8):4201-4211. PubMed ID: 32270317
[TBL] [Abstract][Full Text] [Related]
16. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?
São Julião GP; Habr-Gama A; Vailati BB; Aguilar PB; Sabbaga J; Araújo SEA; Mattacheo A; Alexandre FA; Fernandez LM; Gomes DB; Gama-Rodrigues J; Perez RO
Eur J Surg Oncol; 2018 Jan; 44(1):93-99. PubMed ID: 29217398
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.
Schou JV; Larsen FO; Sørensen BS; Abrantes R; Boysen AK; Johansen JS; Jensen BV; Nielsen DL; Spindler KL
Ann Oncol; 2018 Mar; 29(3):610-615. PubMed ID: 29253083
[TBL] [Abstract][Full Text] [Related]
18. Developing a prediction model based on MRI for pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Wan L; Zhang C; Zhao Q; Meng Y; Zou S; Yang Y; Liu Y; Jiang J; Ye F; Ouyang H; Zhao X; Zhang H
Abdom Radiol (NY); 2019 Sep; 44(9):2978-2987. PubMed ID: 31327039
[TBL] [Abstract][Full Text] [Related]
19. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
[TBL] [Abstract][Full Text] [Related]
20. Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation.
Probst CP; Becerra AZ; Aquina CT; Tejani MA; Wexner SD; Garcia-Aguilar J; Remzi FH; Dietz DW; Monson JR; Fleming FJ;
J Am Coll Surg; 2015 Aug; 221(2):430-40. PubMed ID: 26206642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
